Terms: = Lung cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Diagnosis
472 results:
1. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
2. Temporal trends and regional variability in BRAF and kras genetic testing in Denmark (2010-2022): Implications for precision medicine.
Frost MG; Jensen KJ; Jimenez-Solem E; Qvortrup C; Kuhlmann TP; Andersen JL; Høgdall E; Petersen TS
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23236. PubMed ID: 38656617
[TBL] [Abstract] [Full Text] [Related]
3. Genetic Signature of Human Pancreatic cancer and Personalized Targeting.
Reshkin SJ; Cardone RA; Koltai T
Cells; 2024 Mar; 13(7):. PubMed ID: 38607041
[TBL] [Abstract] [Full Text] [Related]
4. Precision nanomedicine to treat non-small cell lung cancer.
Dessai A; Nayak UY; Nayak Y
Life Sci; 2024 Jun; 346():122614. PubMed ID: 38604287
[TBL] [Abstract] [Full Text] [Related]
5. [Colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological analysis of eight cases].
Wang Q; Zhang Y; Tan C; Ni SJ; Huang D; Chang B; Sheng WQ; Wang L
Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):370-376. PubMed ID: 38556821
[No Abstract] [Full Text] [Related]
6. Integrating image and gene-data with a semi-supervised attention model for prediction of kras gene mutation status in non-small cell lung cancer.
Xue Y; Zhang D; Jia L; Yang W; Zhao J; Qiang Y; Wang L; Qiao Y; Yue H
PLoS One; 2024; 19(3):e0297331. PubMed ID: 38466735
[TBL] [Abstract] [Full Text] [Related]
7. Next-Generation Sequencing in lung cancers-A Single-Center Experience in Taiwan.
Lai WA; Huang YS; Chang KC; Yang SF; Yang CJ; Liu YW; Chen HD
Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399524
[No Abstract] [Full Text] [Related]
8. Effects of different kras mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma.
Wang J; Dong L; Zheng Z; Zhu Z; Xie B; Xie Y; Li X; Chen B; Li P
Sci Rep; 2024 Feb; 14(1):4085. PubMed ID: 38374309
[TBL] [Abstract] [Full Text] [Related]
9. Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced lung Adenocarcinoma: A Case Report.
Tang Q; Li T; Ren F; Li X; Cao W; Yu H; Mao F; Cao C; Zu L; Xu S
J Natl Compr Canc Netw; 2024 Feb; 22(2):. PubMed ID: 38364363
[TBL] [Abstract] [Full Text] [Related]
10. 2021 WHO Classification of lung cancer: Molecular Biology Research and Radiologic-Pathologic Correlation.
Sasaki T; Kuno H; Hiyama T; Oda S; Masuoka S; Miyasaka Y; Taki T; Nagasaki Y; Ohtani-Kim SJ; Ishii G; Kaku S; Shroff GS; Kobayashi T
Radiographics; 2024 Mar; 44(3):e230136. PubMed ID: 38358935
[TBL] [Abstract] [Full Text] [Related]
11. Fusion of old and new: Employing touch imprint slides for next generation sequencing in solid tumors.
Aydin Mericoz C; Eren OC; Kulac I; Firat P
Diagn Cytopathol; 2024 May; 52(5):264-270. PubMed ID: 38339821
[TBL] [Abstract] [Full Text] [Related]
12. Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma".
Shigeta N; Yokose T; Murakami S; Isaka T; Shinada K; Yoshioka E; Narita A; Katakura K; Kondo T; Kato T; Nagashima T; Saito H; Ito H
Thorac Cancer; 2024 Feb; 15(6):458-465. PubMed ID: 38197164
[TBL] [Abstract] [Full Text] [Related]
13. Presentation and outcomes of kras
Esfahanian N; Chan SWS; Zhan LJ; Brown MC; Khan K; Lee J; Balaratnam K; Yan E; Parker J; Garcia-Pardo M; Barghout SH; Eng L; Bradbury PA; Shepherd FA; Leighl NB; Sacher AG; Snow S; Juergens R; Liu G
Cancer Treat Res Commun; 2023; 37():100774. PubMed ID: 37979334
[TBL] [Abstract] [Full Text] [Related]
14. Deciphering signaling pathway interplay via miRNAs in malignant pleural mesothelioma.
Salman A; Abdel Mageed SS; Fathi D; Elrebehy MA; Abulsoud AI; Elshaer SS; Khidr EG; Al-Noshokaty TM; Khaled R; Rizk NI; Elballal MS; Sayed GA; Abd-Elmawla MA; El Tabaa MM; Mohammed OA; Ashraf A; El-Husseiny AA; Midan HM; El-Dakroury WA; Abdel-Reheim MA; Doghish AS
Pathol Res Pract; 2023 Dec; 252():154947. PubMed ID: 37977032
[TBL] [Abstract] [Full Text] [Related]
15. Correlation analysis of clinical, pathological, imaging and genetic features of ground-glass nodule featured lung adenocarcinomas between high-risk and non-high-risk individuals.
Ren J; Wang Y; Liu C; Yang L; Men X; Qiu Z
Eur J Med Res; 2023 Nov; 28(1):478. PubMed ID: 37924162
[TBL] [Abstract] [Full Text] [Related]
16. Do resected colorectal cancer patients need early chest imaging? Impact of clinicopathologic characteristics on time to development of pulmonary metastases.
Deboever N; Bayley EM; Eisenberg MA; Hofstetter WL; Mehran RJ; Rice DC; Rajaram R; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Bednarski BK; Morris VK; Antonoff MB
J Surg Oncol; 2024 Feb; 129(2):331-337. PubMed ID: 37876311
[TBL] [Abstract] [Full Text] [Related]
17. Revolutionizing Non-Small Cell lung cancer diagnosis: Ultra-High-Sensitive ctDNA Analysis for Detecting Hotspot Mutations with Long-term Stored Plasma.
Lee JY; Jeon S; Jun HR; Sung CO; Jang SJ; Choi CM; Chun SM
Cancer Res Treat; 2024 Apr; 56(2):484-501. PubMed ID: 37871897
[TBL] [Abstract] [Full Text] [Related]
18. Adequacy of cytology and small biopsy samples obtained with rapid onsite evaluation (ROSE) for predictive biomarker testing in non-small cell lung cancer.
Hendry S; Mamotte L; Mesbah Ardakani N; Leslie C; Tesfai Y; Grieu-Iacopetta F; Izaac K; Singh S; Ardakani R; Thomas M; Giardina T; Robinson C; Frost F; Amanuel B
Pathology; 2023 Dec; 55(7):917-921. PubMed ID: 37805343
[TBL] [Abstract] [Full Text] [Related]
19. Clinical characteristics of patients with kras mutation detected by liquid biopsy.
Amino Y; Low SK; Ninomiya H; Kiritani A; Miyadera K; Kakuto S; Akita T; Tsugitomi R; Ariyasu R; Uchibori K; Kitazono S; Yanagitani N; Nishio M
Thorac Cancer; 2023 Nov; 14(33):3317-3322. PubMed ID: 37751775
[TBL] [Abstract] [Full Text] [Related]
20. miR-92a-3p regulates cisplatin-induced cancer cell death.
Larrue R; Fellah S; Boukrout N; De Sousa C; Lemaire J; Leboeuf C; Goujon M; Perrais M; Mari B; Cauffiez C; Pottier N; Van der Hauwaert C
Cell Death Dis; 2023 Sep; 14(9):603. PubMed ID: 37704611
[TBL] [Abstract] [Full Text] [Related]
[Next]
